EARLY CLINICAL UTILITY DATA OF A MULTI-ANALYTE BLOOD BIOMARKER TEST FOR EVALUATING COGNITIVE IMPAIRMENT
2024
Blood Test for Evaluating Cognitive Impairment
Sample size: 52
publication
Evidence: high
Author Information
Author(s): Monane Mark, Merrill David, Johnson Kim, Gitelman Darren, Maraganore Demetrius, Jacobs Leslie, Jiang Yan, Braunstein Joel
Hypothesis
The AAA-BBM2 blood test can effectively evaluate cognitive impairment in symptomatic patients.
Conclusion
The AAA-BBM2 test demonstrated clinical utility by significantly changing clinicians' diagnostic certainty and management decisions for patients with cognitive impairment.
Supporting Evidence
- The AAA-BBM2 test has shown 88% sensitivity and 89% specificity.
- Concordance with intended use of the test was 100%.
- Positive APS2 results were noted in 26 patients (50%).
- Clinician-reported probability of AD decreased from 48% to 16% among negative APS2 patients.
- Clinician-reported probability of AD increased from 71% to 93% among positive APS2 patients.
- The composite endpoint of change in AD diagnostic certainty was 79%.
Takeaway
A new blood test can help doctors figure out if someone has Alzheimer's disease by looking at certain markers in their blood.
Methodology
The study evaluated the AAA-BBM2 blood test among cognitively symptomatic patients presenting to memory specialists.
Participant Demographics
Median age 75, 65% female, 77% white.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website